Aurisco Pharmaceutical Co.,Ltd.: history, ownership, mission, how it works & makes money

Founded in 1998, Aurisco Pharmaceutical Co., Ltd. (SHSE: 605116) has transformed from a domestic API and FDF developer into an internationally compliant manufacturer-opening a fermentation-focused Yangzhou facility in 2006, securing USFDA approval for its Tiantai plant in 2013, listing on the Shanghai Stock Exchange in 2020, winning China's first marketing authorization for AUXITON® (dydrogesterone FDF) in 2023, and commissioning a GLP‑1 peptide plant in Yangzhou in 2024; today the company employs over 1,300 people (with 240+ in R&D), operates four production sites and five R&D centers, leverages advanced platforms like photochemistry and flow chemistry, and serves markets across Asia, Europe, the Americas and the Middle East while monetizing through complex APIs, FDF sales and CRDMO contracts-financially highlighted by a market capitalization of ~8.91 billion CNY and a stock price of 22.05 CNY as of October 23, 2025 (an 84.35% market-cap rise since September 21, 2020), a trailing P/E of 21.86 (July 5, 2025) and revenue per employee around 878,390 CNY which underscore its efficiency and growth trajectory

Aurisco Pharmaceutical Co.,Ltd. (605116.SS): Intro

• Founded: 1998 - core focus on complex APIs and FDFs
• Yangzhou Lian'ao fermentation campus established: 2006 - fermentation R&D & production
• Tiantai facility FDA approval: 2013 - enabled exports to U.S. market
• Shanghai Stock Exchange listing: 2020 - stock code 605116.SS
• First NMPA marketing approval in China: 2023 - AUXITON® (oral dydrogesterone)
• Yangzhou GLP‑1 peptide manufacturing facility launched: 2024 - peptide capacity expansion

• 1998-2005: Establishment and early API portfolio build-out focused on complex synthetic and fermentation-derived APIs.
• 2006: Yangzhou Lian'ao established to scale fermentation processes and increase vertical integration of fermentation APIs.
• 2010s: Upgrading of GMP systems; Tiantai achieves U.S. FDA approval in 2013, validating quality systems for export markets.
• 2020: Public listing on the Shanghai Stock Exchange (605116.SS), improving capital access for capacity and R&D investment.
• 2023: AUXITON® (dydrogesterone oral FDF) receives first NMPA marketing authorization - important move into domestic finished formulations.
• 2024: Commissioning of a dedicated GLP‑1 peptide manufacturing facility in Yangzhou to address growing global demand for peptide generics.

• Integrated value chain: discovery → fermentation/synthesis → API manufacture → finished dosage formulation → regulatory approvals and commercialization.
• Multiple technology platforms: microbial fermentation, chemical synthesis, peptide synthesis and sterile fill/finish for sensitive biologically active products.
• Regulatory focus: GMP-compliant facilities with at least one FDA‑inspected site (Tiantai) and NMPA-approved finished dosage registrations.
• Revenue drivers: API sales (domestic & export), FDF product launches (AUXITON® and pipeline), contract manufacturing and toll production for third parties, and emerging peptide generics (GLP‑1).

• AUXITON® (dydrogesterone, oral FDF) - NMPA approval 2023 for gynecological indications.
• Fermentation‑derived antibiotics/complex APIs - long-standing revenue base from Yangzhou production.
• GLP‑1 peptide manufacturing - new capacity for generic GLP‑1 analogs and peptide contract manufacturing (launched 2024).
• FDA‑approved Tiantai site (2013) - enables U.S. API and potentially finished product supply under appropriate approvals.

• API manufacturing - sale of active ingredients to domestic and international pharmaceutical companies; legacy revenue backbone.
• Finished dosage forms - branded generics (e.g., AUXITON®) and development of additional oral/injectable generics for China and export markets.
• Contract manufacturing (CMO) and toll processing - fee‑based manufacturing leveraging fermentation and peptide capacity.
• Pipeline/innovation - R&D investments into peptide generics (GLP‑1) and formulation improvements to capture higher-margin FDF sales.

• Multiple GMP‑compliant manufacturing sites with at least one FDA‑inspected facility (Tiantai).
• Vertical integration from fermentation upstream through FDF fill/finish supports margin capture and supply security.
• Recent NMPA approval demonstrates capability to move molecules from API to marketed pharmaceutical product in China.
• New peptide facility positions the company in a high-growth therapeutic category (GLP‑1 analog generics).

Aurisco Pharmaceutical Co.,Ltd. (605116.SS): History

• Listed: Shanghai Stock Exchange, stock code 605116.SS
• Market cap (Oct 23, 2025): 8.91 billion CNY
• Share price (Oct 23, 2025): 22.05 CNY
• Market cap growth: +84.35% from Sep 21, 2020 to Oct 23, 2025
• Shareholder base: mix of institutional and retail investors

• Publicly traded with dispersed institutional and retail holdings.
• Institutional investors and funds hold a significant portion, contributing to liquidity and governance oversight.
• Management and insiders retain strategic stakes aligning long-term interests with shareholders.

• Develop and deliver innovative, high-quality pharmaceutical products to address clinical needs.
• Invest in R&D and scalable manufacturing to improve patient access and commercial reach.
• Maintain sustainable growth and create shareholder value through pipeline advancement and market expansion.

• R&D: Discovery and clinical development of proprietary drug candidates and formulations; investing part of revenue into pipeline progression.
• Manufacturing: Revenue from commercial-scale production of in-house and contract-manufactured drugs leveraging GMP facilities.
• Commercialization: Sales of marketed products through hospital, retail, and distribution channels across domestic and select export markets.
• Licensing & partnerships: Upfronts, milestones, and royalties from out-licensing or co-development agreements.

Aurisco Pharmaceutical Co.,Ltd. (605116.SS): Ownership Structure

• Mission: Deliver highest-quality pharmaceutical products while driving innovation and sustainable growth.
• Core values: Honesty, integrity, teamwork, customer satisfaction.
• Corporate spirit: Continuous practice, innovation-led excellence.
• Workforce policy: Equal treatment, incentive alignment, harmonious employee environment.
• Sustainability: Ongoing technological R&D and environmental responsibility.

• Listed on the Shanghai Stock Exchange (605116.SS) with both strategic and public shareholders.
• Board composition combines executive management, independent directors and representative directors from strategic shareholders.
• Governance priorities include R&D oversight, quality control, and compliance with PRC pharmaceutical regulations.

• Manufacture and sale of active pharmaceutical ingredients (APIs) and finished dosage forms to domestic hospitals, distributors and export markets.
• Contract manufacturing and custom synthesis for pharmaceutical partners.
• Licensing and royalties from proprietary formulations and technology platforms.
• Value-added services including formulation development, quality control testing and supply-chain solutions.

Aurisco Pharmaceutical Co.,Ltd. (605116.SS): Mission and Values

• Headquarters: Shanghai, China.
• Production footprint: 4 manufacturing sites.
• R&D network: 5 R&D centers.
• Employees: >1,300 total staff, including >240 R&D personnel.
• Global markets: Asia, Europe, North America, Middle East.
• Stock listing: Shanghai Stock Exchange, ticker 605116.SS.

• End-to-end development: medicinal/ process chemistry → pilot scale → commercial manufacture.
• Advanced enabling technologies: photochemistry, flow chemistry, asymmetric hydrogenation, high-performance chromatography, and particle engineering for formulation and solid-state control.
• Regulatory & quality focus: facilities designed and maintained to meet international regulatory inspections and cGMP standards.
• Partnership model: long-term alliances with global pharmaceutical firms to co-develop and manufacture APIs and intermediates.

• CDMO services: fee-for-service and milestone-based contracts for process development, scale-up, and commercial API manufacturing.
• Toll manufacturing & long-term supply agreements: recurring revenue from multi-year supply contracts with global pharma partners.
• Proprietary and licensed products: sales of in-house developed APIs or intermediates where Aurisco holds manufacturing or commercialization rights.
• Value-added technical services: analytics, regulatory support, and custom formulation/particle-engineering services billed as service revenue.

• Partner profile: long-term manufacturing and development agreements with global pharma enterprises (innovators & generics).
• Geographic diversification: direct supply channels across major continents, enabling regulatory dossier support for customers in US, EU, Japan, Korea, and China.

Aurisco Pharmaceutical Co.,Ltd. (605116.SS): How It Works

• Core manufacturing: production of complex small-molecule APIs, intermediates and select FDFs for multiple therapeutic areas.
• CRDMO services: end-to-end R&D, process development, scale-up and commercial supply for third-party pharma companies.
• Commercial supply: direct sales to formulators, generic manufacturers and branded drug companies in Asia, Europe, the Americas and the Middle East.

• Therapeutic coverage: respiratory, cardiovascular, anti-infection, nervous system, anti-tumor and women's health APIs.
• Customer mix: in-licensing partners, generics makers, specialty pharma and global CRDMO clients.
• Geographic reach: supplies to Asia, Europe, the Americas and the Middle East, enabling currency and market diversification.

• Scale and cost efficiency in multi-site manufacturing to lower per-unit costs and improve margins.
• Higher-margin, technically demanding APIs that have fewer competitors and stronger pricing power.
• Long-term supply contracts and CRDMO relationships that provide predictable revenue streams and utilization stability.
• Ongoing R&D and regulatory filings to expand approved product lists and enter new markets.

Aurisco Pharmaceutical Co.,Ltd. (605116.SS): How It Makes Money

• CDMO services: custom synthesis, process development, scale-up and commercial manufacturing for global pharma clients.
• Generic APIs and finished-dosage forms: sales in China following approval of its first domestic generic.
• Peptide manufacturing: recent capacity build-out targeting GLP‑1 peptide APIs and finished products for diabetes/obesity markets.
• Technology licensing and strategic partnerships: chemistry platforms, photochemistry processes and synthetic-biology derived intermediates.
• Export sales: direct supply to Asia, Europe, North America and the Middle East via a global sales network.

• Market position & future outlook: Aurisco holds a leading domestic position in its core technical niches, backed by long‑term contracts with multinational pharmaceutical firms that reinforce recurring revenue streams.
• Growth drivers: continued investment in process innovation, sustainability initiatives, scaling of GLP‑1 peptide capacity, and commercialization of generics and in‑licensed products.
• Internationalization: diversified export footprint reduces single‑market risk and opens higher‑margin opportunities in regulated markets.